Nuvation Bio Inc - Class A

Research Nuvation Bio Inc - Class A (NUVB) on Bullrun: market cap USD 1.95B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerNUVB
• ExchangeNYSE
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 1.95B
• Financial periodFY2025
• RevenueUSD 62.90M
• Revenue growth699.0%
• Net income-USD 204.63M

Valuation Snapshot

latest market cap is USD 1.95B.

About Nuvation Bio Inc - Class A

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo.

Frequently asked questions

What is Nuvation Bio Inc - Class A's market cap?

Nuvation Bio Inc - Class A's market capitalization is USD 1.95B.

What does Nuvation Bio Inc - Class A do?

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer.